A5001462891- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Genetic factors in colorectal cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
Fudan University Shanghai Cancer Center
2018-2024
Shanghai Medical College of Fudan University
2024
Shanghai Clinical Research Center
2024
Shanghai Institute of Hematology
2024
PURPOSE To assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy patients proficient mismatch repair or microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC). PATIENTS AND METHODS We conducted prospective, multicenter, randomized, open-label, phase II trial using pick-the-winner design. Eligible clinical T3-4 and/or N+ adenocarcinoma were randomly...
D2 surgery followed by adjuvant chemotherapy has been established as the standard of care for patients with locally advanced gastric cancer in Asian countries. However, its efficacy is still unsatisfactory, especially pathological N3 disease. The RACING trial a randomized, multicenter, Phase III designed to compare and safety alone versus combination PD-1 inhibitor radiotherapy pN3 or gastroesophageal junction adenocarcinoma. A total 433 will be assigned at 1:1 ratio two arms. primary end...